Yaskawa Electric Corporation and Astellas Pharma Announce Innovative Collaboration to Develop a Cell Therapy Platform
Yaskawa Electric Corporation and Astellas Pharma have announced an innovative collaboration to develop a cell therapy platform that combines robotic and pharmaceutical technologies. This partnership has the potential to revolutionize the production of cell therapies, facilitating the transition from initial research to commercialization.
The Project and Its Objective
The memorandum of understanding (MOU) signed by both companies aims to create a cell therapy ecosystem that can efficiently integrate research and development with commercial production. The main objective is to improve the quality of cell therapy products and shorten development time, which could be especially beneficial for startups and academic institutions facing significant challenges in commercializing cell therapies.
Technology and Collaboration
Yaskawa will bring its expertise in industrial robotics and automation, while Astellas Pharma will contribute its knowledge in cell manufacturing technology and clinical development. The envisioned platform will utilize the Maholo humanoid robot, developed by Yaskawa‘s Robotic Biology Institute, for the production of high-quality products. This robot has been used since late 2017 in the research and development of drug manufacturing technologies.
Potential Benefits
The collaboration has the potential to reduce investment costs in the manufacturing of investigational drugs, facilitating technology transfer and establishing large-scale production facilities. Additionally, the platform could offer beneficial services that contribute to innovation in the field of cell therapy, supporting the discovery and development of new treatments.
Vision and Commitment
Astellas Pharma is committed to being at the forefront of change in healthcare, turning innovative science into value for patients. This partnership with Yaskawa is a step towards realizing this vision, providing startups and academia with advanced tools for the development of innovative cell therapies.
The collaboration between Yaskawa and Astellas Pharma represents a significant advancement in the field of cell therapy, combining robotic and pharmaceutical technologies to improve production efficiency and quality. This partnership has the potential to transform the cell therapy industry, facilitating the commercialization of innovative treatments and contributing to the advancement of regenerative medicine.
If you need more info, don’t hesitate to call us: we will be ready to help you and to find the best solution for you project.